Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$2.45 USD
+0.06 (2.51%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.46 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Price, Consensus and EPS Surprise
TSHA 2.45 +0.06(2.51%)
Will TSHA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TSHA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TSHA
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?
TSHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Wall Street Analysts Believe Taysha Gene Therapies, Inc. (TSHA) Could Rally 608%: Here's is How to Trade
Other News for TSHA
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
Apple upgraded, Tesla downgraded: Wall Street's top analyst calls
Neurogene initiated with bullish view at Leerink, here's why
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call